Case report

‘Malignant’ hypertension from hyperaldosteronism: a case report

Krishna Mohan Baradhi1,8, Thao Tran1, Penchala Swamy Mittadodla2

1University of Oklahoma, Department of Internal Medicine/Nephrology, Tulsa Schusterman Center, Tulsa, Oklahoma, USA, 74135, 2Mercy Clinic, Critical Care Medicine, Rogers, Arkansas, USA, 72758

8Corresponding author: Krishna Mohan Baradhi, University of Oklahoma, Department of Internal Medicine/Nephrology, Tulsa Schusterman Center, Tulsa, Oklahoma, USA, 74135

Key words: Secondary hypertension, hyperaldosteronism, adrenocortical carcinoma, hypokalemia

Received: 01/10/2017 - Accepted: 22/04/2018 - Published: 04/05/2018

Abstract

Adrenocortical carcinomas (ACC) are rare with an incidence of 0.7-2 per million population per year and account for only 0.05%-2% of all malignant tumors. While majority of the functional ACC present as Cushing syndrome, recurrent hyperaldosteronism from metastatic ACC is exceedingly rare. We describe a 67-year old female presented with hypertensive urgency & hypokalemia as a result of hyperaldosteronism from an 8-cm right ACC. She underwent a radical right nephrectomy with adrenalectomy that normalized her blood pressure. However, a few years later she presented again with resistant hypertension from hyperaldosteronism, raising the suspicion of recurrence of ACC. A contrast-enhanced CT scan showed a normal left adrenal gland but revealed pulmonary metastases of ACC based on a lung biopsy. Chemotherapy was complicated with side effects leading to refusal of further chemotherapy, henceforth requiring high dose of spironolactone for blood pressure control. Despite curative surgery, metastatic functional ACC should be considered in patients presenting with secondary hypertension from recurrent hyperaldosteronism, due to its high recurrence rate. Besides standard cancer surveillance after a curative surgery, meticulous monitoring of blood pressure is a simple yet crucial way to detect cancer recurrence early.

Pan African Medical Journal. 2018; 30:10 doi:10.11604/pamj.2018.30.10.14015

This article is available online at: http://www.panafrican-med-journal.com/content/article/30/10/full/

© Krishna Mohan Baradhi et al. The Pan African Medical Journal - ISSN 1937-8688. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Introduction

Adrenocortical carcinomas (ACC) are rare malignancies with an incidence of 0.7-2 per million population per year [1]. While ~60% of ACC are functional, clinical manifestations of hyper-secretion are seen in only ~40% of the cases. Hormone-secreting ACC usually present as Cushing’s syndrome (45%), or a mixed Cushing’s and virilization syndrome, (25%), whereas, aldosterone-producing tumors are exceptionally rare comprising only ~2.5% of ACC. Amongst these unfamiliar territories, hyperaldosteronism from metastatic adrenal carcinoma has rarely been reported. We herein present a first unique case of secondary hypertension as a result of hyperaldosteronism arising from lung metastasis of the previously resected ACC.

Patient and observation

The patient is a 67-year-old Caucasian woman who presented with uncontrolled hypertension. Patient did not have major medical issues until her early 60s when she started noticing rise in blood pressure during her routine clinic visits. Physical examination was within the normal limits except her systolic blood pressure was consistently in the 200s. Laboratory evaluation was significant for hypokalemia of 2.7 meq/L, bicarbonate -24 meq/L and creatinine of 0.92 mg/dl. Further evaluation for possible etiology of secondary hypertension revealed high aldosterone-renin ratio. Computed tomography (CT) scan to evaluate hyperaldosteronism showed a large mass in right adrenal gland measuring 10 x 7.8 cm (Figure 1). Further FDG-PET scan showed a right adrenal mass and periceliac lymph nodes were positive. The patient underwent a radical right adrenalectomy with nephrectomy and lymph nodes dissection. Pathology revealed 14 cm adrenal cortical carcinoma with two lymph nodes next to vena cava which were positive. She also completed adjuvant radiation and chemotherapy. Her blood pressure and serum potassium normalized after adrenalectomy. Follow up FDG-PET scan a year later showed increase glucometabolism in a nodal mass of the left paratracheal region superior to the clavicle and underwent lymph node dissection. Biopsy again showed metastatic ACC of supraclavicular lymph node. Patient completed 3 cycles of carboplatin and etoposide. In addition, during this time, the patient also diagnosed with papillary thyroid carcinoma for which she underwent thyroidectomy and ablation. Blood pressure was within the normal limits during this period. Patient was compliant until she presented back again with difficult to control blood pressure with associated hypokalemia. Further evaluation for possible recurrence of ACC. A CT abdomen showed normal left adrenal gland, however CT chest revealed multiple pulmonary lesions favoring metastasis as shown in the Figure 2. Initial bronchoscopy showed many atypical cells but no malignancy. Percutaneous lung biopsy unveiled these lesions to be of metastatic cancer of adrenocortical origin. She underwent chemotherapy again complicated with side effects leading to refusal of further chemotherapy, henceforth requiring high dose of spironolactone (400 mg daily) for blood pressure control.

Discussion

Secondary hypertension from aldosterone secreting ACC is not only uncommon but may also be unfamiliar to the practicing clinicians. Amongst these odd etiologies of hyperaldosteronism, pulmonary metastasis of previously resected ACC is a rare entity. Deckers et al reported a case of hyperaldosteronism from peritoneal dissemination of the previously removed ACC [2]. Calvo-Romero et al reported a case of resistant hypertension as a result of hyperaldosteronism from recurrent adrenal adenoma [3]. ACC usually affect middle aged group and are slightly more common in females [4]. The clinical presentation of aldosterone producing ACC is hypertension and hypokalemia. It is clinically indistinguishable from the Conn’s syndrome presentation and pathological differentiation can be challenging. Both size and appearance on imaging are used to distinguish between benign and malignant adrenal mass. Tumors > 6cm are highly suspicious for malignancy and require surgical resection according to NIH [5]. For tumors between 4 and 6 cm, additional criteria should be considered before adjudicating to monitor or proceed to adrenalectomy [5]. In addition, Weiss criteria can also be used to distinguish between benign and malignant ACC. Weiss system mandates meeting three out of the nine histological features to be regarded as malignant [6]. Amongst them, the presence of atypical mitoses, capsular invasion, tumor weight greater than 250g, and size greater than 10cm each showed a statistical association with poor survival, compared to other features, such as nuclear grade, presence of necrosis or of venous/sinusoidal invasion, character of the tumor cell cytoplasm, or architectural pattern, showed no statistical significance in predicting survival [7].

Mineralocorticoid antagonists or adrenalectomy can be the option of treatment for classical causes of primary hyperaldosteronism, whereas the only potential lifesaving option for ACC is complete radical resection [8]. It is imperative that hormonal assessment is done prior to adrenalectomy. Despite surgical resection, there is a high recurrence rate of ACC, up to 74% recurrence rate either local or distant metastasis [9]. Hence, Fassnacht et al advocate periodic radiological and biochemical monitoring for at least 10 years post-surgery for ACC [4]. For aldosterone producing ACC, common sites of metastasis include liver, lung, abdominal lymph nodes, contralateral adrenal and abdominal lymph nodes [10]. The prognosis of ACC depends on tumour stage and is generally poor. Interval between the initial resection of an adrenocortical carcinoma and recurrence can dictate prognosis [11]. The overall 5-year survival rate range between 16 and 38% and median survival for metastatic disease is less than 12 months [12,13]. Largest study to date indicated rates of response and progression-free survival were significantly better with etoposide plus mitotane than with streptozocin plus mitotane as first-line therapy for advanced ACC [14]. Our patient presented with recurrent metastatic ACC with resultant hyperaldosteronism leading to resistant hypertension and hypokalemia. Given the extent of her disease with multiple recurrences of metastasis, mitotane chemotherapy was offered to patient along with the etoposide. Unfortunately, as she succumbed to the side effects of therapy, patient decided against further treatment and required escalating doses of spironolactone to control her blood pressure.

Conclusion

Our case highlights the importance of considering functional ACC in patients presenting with hyperaldosteronism. Clinicians should be cognizant of high rate of recurrence of ACC and incorporate blood pressure monitoring besides standard radiographic and laboratory
surveillance after a curative surgery to detect recurrence of ACC early.

Competing interests

The authors declare no competing interests.

Authors’ contributions

All authors read and agreed to the final version of this manuscript and equally contributed to its content and to the management of the case.

Table and figures

Table 1: Laboratory data

Figure 1: CT abdomen: (A) coronal section showing 8cm mass above the right kidney; (B) sagittal section showing the adrenal tumor

Figure 2: CT chest showing bilateral pulmonary metastases

References

1. Allolio B, Fassnacht M. Clinical review: Adrenocortical carcinoma: Clinical update. J Clin Endocrinol Metab. 2006; 91(6): 2027-2037. PubMed | Google Scholar

2. Deckers S, Derdelinckx L, Col V, Hamels J & Maiter D. Peritoneal carcinomatosis following laparoscopic resection of an adrenocortical tumor causing primary hyperaldosteronism. Hormone Research. 1999; 52: 97-100. PubMed | Google Scholar

3. Calvo-Romero JM, Ramos-Salado JL. Recurrence of adrenal aldosterone-producing adenoma. Postgrad Med J. 2000; 76(893): 160-161. PubMed | Google Scholar

4. Fassnacht M, Kroiss M, Allolio B. Update in adrenocortical carcinoma. J Clin Endocrinol Metab. 2013; 98(12): 4551. PubMed | Google Scholar

5. National Institutes of Health. NIH state-of-the-science statement on management of the clinically inapparent adrenal mass ("incidentaloma"). NIH Consens State Sci Statements. 2002; 19(2): 1-25. PubMed | Google Scholar

6. Weiss LM. Comparative histologic study of 43 metastasizing and nonmetastasizing adrenocortical tumors. Am J Surgical Pathology. 1984; 8(3): 163-169. PubMed | Google Scholar

7. Weiss LM, Medeiros LJ, Vickery AL Jr. Pathologic features of prognostic significance in adrenocortical carcinoma. Am J Surgical Pathology. 1989 Mar; 13(3): 202-6. PubMed | Google Scholar

8. Allolio B, Hahner S, Weismann D, Fassnacht M. Management of adrenocortical carcinoma. Clinical Endocrinology. 2004; 60(3): 273-87. PubMed | Google Scholar

9. Freire DS, Siqueira SA, Zerbini MC, Wajchenberg BL, Corrêa-Giannella ML, Lucon AM et al. Development and internal validation of an adrenocortical carcinoma prognostic score for predicting the risk of metastasis and local recurrence. Clinical Endocrinology. 2013; 79(4): 468-475. PubMed | Google Scholar

10. Seccia TM, Fassina A, Nussdorfer GG, Pessina AC, Rossi GP. Aldosterone-producing adrenocortical carcinoma: an unusual cause of Conn's syndrome with an ominous clinical course. Endocrine Related Cancer. 2005; 12(1): 149-159. PubMed | Google Scholar

11. Simon G, Pattou F, Mirallié E, Lifante JC, Nominé C, Arnault V, de Calan L, Caillard C, Carnaille B, Brunaud L, Laplace N, Caiazzo R, Blanchard C. Surgery for recurrent adrenocortical carcinoma: a multicenter retrospective study. Surgery. 2017; 161(1): 249-256. PubMed | Google Scholar

12. Luton JP, Cerdas S, Billaud L, Thomas G, Guilhaume B, Bertagna X, Laoudat MH, Louvel A, Chapuis Y, Blondeau P et al. Clinical features of adrenocortical carcinoma, prognostic factors, and the effect of mitotane therapy. New England Journal of Medicine. 1990; 322(17): 1195-1201. PubMed | Google Scholar

13. Icard P, Goudet P, Charpenay C, Andreassian B, Carnaille B, Chapuis Y, Cougard P, Henry JF, Proye C. Adrenocortical carcinomas: surgical trends and results of a 253-patient series from the French Association of Endocrine Surgeons Study Group. World Journal of Surgery. 2001; 25(7): 891-897. PubMed | Google Scholar

14. Fassnacht M, Terzolo M, Allolio B et al. Combination chemotherapy in advanced adrenocortical carcinoma. N Eng J Med 2012; 366: 2189-2197. Google Scholar
Table 1: Laboratory data

| Chemistry | Initial presentation | Recurrent presentation | Units |
|-----------|----------------------|------------------------|-------|
| Sodium    | 136                  | 140                    | mEq/L |
| Potassium | 2.7                  | 3.1                    | mEq/L |
| Chloride  | 104                  | 106                    | mEq/L |
| Bicarbonate | 24               | 25                     | mEq/L |
| Calcium   | 8.7                  | 8.8                    | mEq/L |
| Creatinine| 0.92                 | 1.13                   | mEq/L |
| BUN       | 14                   | 15                     | mg/dL |
| Glucose   | 133                  | 88                     | mg/dL |
| Aldosterone/Renin ratio | >200               |                        |       |

Figure 1: CT abdomen: (A) coronal section showing 8cm mass above the right kidney; (B) sagittal section showing the adrenal tumor
Figure 2: CT chest showing bilateral pulmonary metastases